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We describe a novel, potent and selective orexin-2 (OX2)/hypocretin-2 receptor
antagonist with in vivo activity in an animal model predictive of antidepressant-like
efficacy. N-biphenyl-2-yl-4-fluoro-N-(1H-imidazol-2-ylmethyl) benzenesulfonamide HCl
(LSN2424100) binds with high affinity to recombinant human OX2 receptors (Ki = 4.5nM),
and selectivity over OX1 receptors (Ki = 393nM). LSN2424100 inhibited OXA-stimulated
intracellular calcium release in HEK293 cells expressing human and rat OX2 receptors
(Kb = 0.44 and 0.83 nM, respectively) preferentially over cells expressing human and
rat OX1 (Kb = 90 and 175 nM, respectively). LSN2424100 exhibits good exposure
in Sprague–Dawley rats after IP, but not PO, administration of a 30mg/kg dose
(AUC0 6 h = 1300 and 269 ng∗h/mL, respectively). After IP administration in rats−
and mice, LSN2424100 produces dose-dependent antidepressant-like activity in the
delayed-reinforcement of low-rate (DRL) assay, a model predictive of antidepressant-like
efficacy. Efficacy in the DRL model was lost in mice lacking OX2, but not OX1 receptors,
confirming OX2-specific activity. Importantly, antidepressant-like efficacy of the tricyclic
antidepressant, imipramine, was maintained in both OX1 and OX2 receptor knock-out
mice. In conclusion, the novel OX2 receptor antagonist, LSN2424100, is a valuable tool
compound that can be used to explore the role of OX2 receptor-mediated signaling in
mood disorders.
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INTRODUCTION
The orexin (or hypocretin) family of neuropeptides, termed
orexin-A (OXA) and orexin-B (OXB), and the receptors to which
they bind, were first identified in the late 1990’s (De Lecea
et al., 1998; Sakurai et al., 1998). The orexin peptides bind to
two G-protein coupled receptors, orexin-1 (OX1) and orexin-2
(OX2), with OXA showing roughly equal affinity for OX1 and
OX2 receptors and OXB binding preferentially to OX2 receptors
(Spinazzi et al., 2006). Although orexin-containing neurons are
predominantly localized in the lateral and posterior hypothala-
mus, they send widespread projections throughout the neuro-axis
(Spinazzi et al., 2006). Orexin has been demonstrated to play
a role in mediating feeding (Sakurai et al., 1998), regulation of
sleep/wake states (Chemelli et al., 1999), addiction and reward-
seeking behavior (Richards et al., 2008; Aston-Jones et al., 2009),
monoaminergic transmission (Borgland et al., 2008; Ortega et al.,
2012), and stress modulation (Boutrel et al., 2005). That many
of these functions are often dysregulated in depression has led
researchers to propose that orexins may be involved in the patho-
physiology of depression (reviewed in Nollet and Leman, 2013).
The exact role of orexins in modulating mood and depres-
sive disorders has proven more difficult to delineate. Early clinical
studies evaluating the potential role of orexin in depressive dis-
orders indicated that depressed patients had a blunted diurnal
variation in CSF orexin-A levels accompanied by higher orexin-
A levels at night, and that these differences were improved with
antidepressant treatment, suggesting a link between disrupted
orexin signaling and HPA axis disruption associated with depres-
sion (Salomon et al., 2003). However, later studies reported
contradictory findings, specifically that CSF orexin-A levels were
decreased in depressed patients who had attempted suicide
(Brundin et al., 2007). To better understand the role of orexin sig-
naling in depression, some researchers turned to putative genetic
animal models of depression, although these studies also pro-
duced seemingly contradictory findings. For example, it has been
demonstrated that Wistar–Kyoto rats, long-regarded as a genetic
model of depression based on enhanced sensitivity to stress
and reduced sensitivity to selective serotonin reuptake inhibitors
(SSRIs; Lopez-Rubalcava and Lucki, 2000), exhibit reduced num-
bers of orexin neurons, as well as smaller soma size, lower
prepro-orexinmRNA expression, and lower OXA levels in various
brain areas (Taheri et al., 2001; Allard et al., 2004). The Flinders
Sensitive Line (FSL) is another line of selectively bred animals
with a prodepressive phenotype characterized by reduced body
weight, reduced sexual behavior, disrupted sleep/wake patterns
(particularly REM sleep) and exaggerated immobility responses
in the Porsolt Forced swim test (Overstreet and Wegener, 2013).
In contrast to results in Wistar–Kyoto rats, the FSL rats were
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found to have a higher number of OX-immunopositive hypotha-
lamic neurons associated with higher immobility in the forced
swim test (Mikrouli et al., 2011). Recently, Nollet et al. (2011)
reported that unpredictable chronic mild stress was associated
with increased aggression and activation of orexin neurons in
the dorsomedial hypothalamus, along with concomitant reduc-
tions in the number of OX2, but not OX1, receptors in ven-
tral hippocampus, thalamus and hypothalamus. Interestingly,
these effects were reversed by chronic treatment with the SSRI
antidepressant, fluoxetine (Nollet et al., 2011). The dual orexin
receptor antagonist, almorexant, has also been shown to pro-
duce antidepressant-like effects in the chronic unpredictable
mild stress model (Nollet et al., 2012). While accumulating evi-
dence suggests that orexin neurotransmission may play a role
in modulating mood states, little is known about the molecular
mechanisms involved.
A more thorough understanding of the involvement of the
orexin system in mediating depression, a complex disorder with
multiple behavioral sequelae, would benefit from the availability
of precise pharmacological probes from multiple chemical scaf-
folds. These, in turn, could lead to the development of novel
pharmacotherapies targeting the orexin system that could prove
beneficial in treating depressive disorders. The OX1 antagonist
SB334867 (Smart et al., 2001), and the dual orexin antagonist,
almorexant (Brisbare-Roch et al., 2007), have been broadly uti-
lized in preclinical experiments. Although OX2-selective antago-
nists have been reported in the literature, including TCS-OX2-29
(Hirose et al., 2003), JNJ-10397049 (McAtee et al., 2004), and
EMPA (Malherbe et al., 2009), very little has been published
on these molecules, especially with regard to antidepressant-like
efficacy.
Here, we describe a novel OX2 receptor antagonist N-
((1H-imidazol-2-yl)methyl)-N-([1,1′-biphenyl]-2-yl)-4-fluorob
enzenesulfonamide hydrochloride (LSN2424100, Figure 1), and
characterize it in terms of its in vitro binding affinity, functional
selectivity, and pharmacokinetic properties, and further examine
its effects on c-fos expression in the rat prefrontal cortex, a
brain region implicated in the pathophysiology of depression
(Drevets et al., 2008), in response to restraint stress. We then
contrast the effects of this compound in an established animal
model predictive of antidepressant-like efficacy, the differential
reinforcement of low-rate (DRL) schedule of reinforcement, in
both rat (DRL-72; O’Donnell et al., 2005), and mouse (DRL-36;
Zhang et al., 2009), as well as mice lacking OX1 and OX2 recep-
tors. The DRL model has been pharmacologically validated for
detecting antidepressant-like efficacy using clinical antidepres-
sants across multiple pharmacological classes, including tricyclic
antidepressants, SSRIs, norepinephrine reuptake inhibitors, and
monoamine oxidase inhibitors as indicated by reduced impulsiv-
ity, improved response inhibition, and improved response timing
(O’Donnell et al., 2005; Zhang et al., 2009).
MATERIALS AND METHODS
DRUGS AND REAGENTS
N-((1H-imidazol-2-yl)methyl)-N-([1,1′-biphenyl]-2-yl)-4-fluo
robenzenesulfonamide hydrochloride (LSN2424100), SB334867,
and both (S)-almorexant (ACT-078573; Weller et al., 2005)
and its inactive enantiomer (R)-almorexant were synthesized
at Lilly Research Laboratories (Indianapolis, IN; see Figure 1).
LSN2424100 and SB334867 were suspended in a solution of 1%
carboxymethylcellulose, 0.25% polysorbate 80, and 0.05% Dow
antifoam and injected IP in a volume of 10ml/kg body weight for
mice and 1ml/kg in rat (LSN2424100 was injected in a 2ml/kg
volume for c-fos studies). (S)-almorexant and (R)-almorexant
were suspended in a solution of 1% carboxymethylcellulose,
0.25% polysorbate 80, and 0.05% Dow antifoam and dosed
PO in a volume of 2ml/kg in rat (dosed IP at 10ml/kg for
mice). Imipramine and alprazolam were purchased from Sigma-
Aldrich (St. Louis, MO). Imipramine was dissolved in sterile
water. Alprazolam was dissolved in 10% 2-hydroxypropyl-β-
cyclodextrin. Drugs were mixed fresh on the day of the experi-
ment and doses were calculated based on the free base weight.
SUBJECTS
Adult Male Sprague–Dawley rats weighing 200–225 g (Harlan,
Indianapolis, IN for c-fos experiments) were housed 4 per cage
with ad libitum access to food (Teklad 4%Rat Diet; Harlan Teklad,
Madison, WI) and water (except during experimental sessions)
and maintained on a 12 h light:dark cycle (lights on at 0600 h).
Rats were acclimated to housing conditions for 4 days, followed
by sham dosing once daily for 3 days, prior to the experiment. For
DRL experiments, male Sprague–Dawley rats weighing between
300 and 350 g at the beginning of the behavioral experiments
(Holtzman, Madison, WI) were housed in pairs. For mouse DRL
studies, male C57Bl/6mice (Taconic Farms, Hudson, NY) ormice
lacking either OX1 or OX2 receptors, around 8 weeks of age,
were obtained from private breeding colonies at Taconic Farms
FIGURE 1 | Chemical structure of LSN2424100 (A), SB334867 (B), and
almorexant (C).
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(Hudson, NY). OX1 and OX2 receptor knockout mice were gen-
erated using in vitro fertilization of embryos in C57Bl/6 female
mice with sperm harvested from male mice obtained from the
University of Texas Southwestern Medical Center (Dallas, TX),
and backcrossed for at least 10 generations. Mice and rats were
housed in separate colony rooms, which were maintained at 22◦C
and 60% relative humidity. For rat DRL experiments, water was
available for a 20-min period following the daily behavioral ses-
sion. Based on recommendations from the animal care and use
committee, themouse DRL assay was developed using food depri-
vation rather than water deprivation. Mice had free access to
water except during experimental sessions, were maintained at
85% of free-feeding weight, and received 1 h of free-feeding after
each experimental session. All experiments were conducted dur-
ing the light cycle and in compliance with the Guide for the Care
and Use of Laboratory Animals under protocols approved by a
local animal care and use committee.
RADIOLIGAND BINDING
Recombinant humanOX1 or OX2 receptors were stably expressed
in HEK293 cells and grown in DMEM/F-12 (3:1) supple-
mented with 5% FBS, 20mM HEPES, 100 ug/ml Penn/Strep,
and 500 ug/ml geneticin. Briefly, the membranes were iso-
lated by homogenizing cell pellet in 30ml (w/v) 50mM Tris
buffer (pH 7.4) containing Roche Complete EDTA free protease
tablets. Membranes were incubated with ∼0.25 nM [125I]-Orexin
A (PerkinElmer, Inc., Waltham, MA) for 90min at 22◦C in
polystyrene 96-deep well plates. All binding studies were con-
ducted at a final volume of 200μl. The assay buffer contained
25mM HEPES, 2.5mM CaCl2, 1.0mM MgCl2, 0.5% BSA, and
0.125% BSA (pH 7.4). To generate binding affinity (Ki), 11 dif-
ferent compound concentrations were incubated with ∼15μg
of OX1 membrane or ∼50μg of OX2 membrane in the pres-
ence of [125I]-Orexin A. Compounds were solubilized to make
a 10mM stock in DMSO then diluted to 40μM by placing
4μl into 996μl binding assay buffer. Then 300μl of this solu-
tion was placed in column B on a Nunc polypropylene 96-well
plate (Thermo Fisher Scientific, Inc., Rochester, NY). Serial dilu-
tions were then made using a Biomek 2000 (Beckman Coulter,
Inc., Fullerton, CA) from a starting concentration of 40μM.
Non-specific binding was determined in these experiments using
10μM SB-334867 and LSN2158312 for OX1 and OX2, respec-
tively. All binding was terminated by rapid filtration using a
TOMTEC 96-well cell harvester (Hamden, CT) through GF/A fil-
ters that had been presoaked with 0.3% polyethyleneimine. The
filters were washed with 5.0ml ice-cold 50mM Tris buffer (pH
7.4) and air-dried overnight. The dried filters were treated with
MeltiLex A (PerkinElmer, Inc., Waltham, MA) melt-on scintilla-
tor sheets, and the radioactivity retained on the filters counted
using a Wallac 1205 Betaplate (PerkinElmer, Inc., Waltham, MA)
scintillation counter. Protein concentrations were measured using
Coomassie Protein Plus Assay Reagent (Pierce, Rockford, IL) and
serum albumin standards. Ki-values from displacement of [125I]-
orexin-A binding were calculated based on 11-point dilution
curves using ActivityBase templates (ID Business Solutions, Ltd.,
Guildford, Surrey, UK). Reported values are shown as a mean ±
the standard error of the mean (s.e.m.).
INTRACELLULAR CALCIUMMOBILIZATION
Recombinant human OX1 and OX2 receptors were stably
expressed in HEK293 cells, or rat recombinant OX1 and OX2
receptors stably expressed in AV12 cells, and assessed for intracel-
lular calcium mobilization using Fluo-3 dye (Molecular Probes,
Eugene, OR). Fluo-3 dye was made at 2.2mM in equal parts
of Pluronic f-127 (Molecular Probes, Eugene, OR) and 100%
DMSO. It was further diluted to 8mM in 2.5mM probenecid
loading buffer which was made as described below. The human
cell line was grown in DMEM/F-12 (3:1) supplemented with
10% FBS (heat-inactivated), 20mM HEPES, 1% Penn/Strep,
and 4μg/ml Blasticidin (35,000 cells/well). The rat cell line was
grown inDMEM supplemented with 10% FBS (heat-inactivated),
20mM HEPES, 1% Penn/Strep, 4μg/ml Blasticidin, and 1mM
sodium pyruvate (60,000 cells/well). Cells were plated in Biocoat
black poly-d-lysine coated clear bottom 96-well plates (Becton
Dickinson, Bedford, MA), allowed to attach for 30min at room
temperature, and then grown overnight at 37◦C and 5% CO2 in
a humidified incubator. Probenecid loading buffer was made at
250mM in equal parts of 1N NaOH and HBSS. It was further
diluted to 2.5mM in HBSS containing calcium and magnesium
+20mM HEPES. The agonist used in this study was Orexin-A
(Bachem/Peninsula Laboratories, San Carlos, CA) dissolved in
de-ionized water at a stock concentration of 80μM. An EC70
concentration of orexin A in 0.1% BSA (Sigma Aldrich, St.
Louis, MO) in HBSS with calcium and magnesium, was used
to challenge the antagonists. Compounds were serial diluted
1:3 from a 10mM stock in DMSO on a Biomek (Beckman
Coulter, Inc., Fullerton, CA) and further diluted in HBSS con-
taining calcium and magnesium +0.04% Bacitracin (USB Corp.,
Cleveland, OH). The assay was performed with the following
steps: (1) growth medium was removed and cells were washed
with 30μl HBSS (with calcium and magnesium) and then
removed. Next, 30μl of dye was added to the wells, and cell
plates were incubated in the dark at room temperature for 60min;
dye was removed, cells were washed with 30μl probenecid load-
ing buffer and removed, and then 50μl of probenecid loading
buffer was added to the wells. Finally, plates were read on a flu-
orescence imaging plate reader (FLIPR; Molecular Devices, LLC,
Sunnyvale, CA) instrument with a 50μl addition of antagonist;
cells were placed in the dark at room temperature for an addi-
tional 15min; then read on FLIPR instrument with a 100μl
addition of an EC70 concentration of orexin A (for a total vol-
ume of 200μl). Final concentrations of the test compounds were
20μM in 1.25% DMSO and 10μM in 0.625% DMSO for the
two different FLIPR reads, respectively. Kb-values were calculated
based on 10-point dilution curves using ActivityBase templates
(ID Business Solutions, Ltd., Guildford, Surrey, UK). Reported
values are shown as a mean ± the standard error of the mean
(s.e.m.).
RAT EXPOSURE AND UNBOUND FRACTION
Two male cannulated rats were administered a single 30mg/kg
intraperitoneal (IP) or 30mg/kg oral (PO) dose of LSN2424100 to
determine the pharmacokinetic parameters. Plasma samples were
collected at 0.5, 1, 1.5, 2, 4, and 6 h post-dose and analyzed by liq-
uid chromatography coupled to tandem mass spectral detection
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(LC-MS/MS) to determine the concentrations of LSN2424100.
Two cohorts of rats were used in each study, with samples taken
from one cohort at 0.5, 1, and 2 h post-dose, and samples taken
from the second cohort at 1.5, 4, and 6 h post-dose. The first
cohort of animals was sacrificed at 2 h post-dose, and the sec-
ond at 6 h post-dose to allow for collection of brain samples.
The plasma and brain binding of LSN2424100 were determined
by equilibrium dialysis at 1μM which were used to calculate
unbound concentrations in brain and plasma at 2 h post-dose
(Zamek-Gliszczynski et al., 2011).
RESTRAINT-STRESS-INDUCED c-FOS ACTIVATION
Beginning at 0830 h on the day of the study, groups of rats
(n = 8 per group) received IP injections of vehicle, 30mg/kg
LSN2424100, or 3mg/kg alprazolam in a counter-balanced man-
ner and were returned to the home cage. Thirty min later,
rats were restrained in a rigid plastic flat-bottom restraint tube
(Braintree Scientific, Inc.; Braintree, MA, USA) for 20min. After
the 20min stress period, rats were moved to a new cage and
housed individually. Rats were sacrificed 2 h after stress onset.
Separate groups of control animals (n = 6 − 8 each) received
either vehicle or 30mg/kg LSN2424100 and were returned to
their home cage until sacrifice. Immediately after sacrifice, brains
were removed, the medial prefrontal cortex (mPFC), a brain area
implicated in the pathophysiology of depression, was dissected
from both hemispheres and frozen in 1.5ml centrifuge tubes in
dry ice, and stored at −80◦C for later analysis.
c-Fos ELISA ANALYSIS
Frozen mPFC tissues were removed from the −80◦C freezer and
placed on ice. Tissue was homogenized with a dounce homoge-
nizer. The nuclear extract was prepared from the homogenized
samples as per manufacturer’s instructions using a CHEMICON
®Nuclear Extraction Kit (Millipore; Billerica, MA, USA). Protein
concentrations were determined in the nuclear extracts using
the Pierce BCA Protein Assay kit (Pierce Biotechnology, Inc.,
Rockford, IL, USA). Nuclear fractions were then assayed for Fos
protein levels using the Pierce c-Fos Transcription Factor Kit
(Pierce Biotechnology, Inc., Rockford, IL, USA), according to
the manufacturer’s instructions. A Wallac 1420VICTOR lumi-
nometer (PerkinElmer; Waltham,MA, USA) was used to measure
chemiluminesence in the ELISA plates. Data were analyzed and
plotted using GraphPad Prism (GraphPad Software, Inc.; La Jolla,
CA, USA).
RAT APPARATUS AND TRAINING
Sixteen operant-conditioning chambers (30.5 × 24.1 × 29.2 cm;
MED Associates, St. Albans, VT) were utilized in conducting the
DRL experiments. Each chamber was enclosed in a melamine
sound-attenuating cubicle. A white noise generator provided
masking noise. The interior of each chamber consisted of three
levers mounted on one wall with a house light mounted on the
opposite wall. The house light was turned on at initiation of each
test session and was turned off at the termination of each session.
A water access port was situated next to the lever in the middle of
the wall, wherein a reinforced response caused a clicker apparatus
to sound paired with a dipper (0.02-ml cup) to be lifted from a
water trough to an opening in the floor of the access port for 4 s.
Rats were water deprived for ∼22.5 h before each session. Rats
were initially trained under an alternative fixed ratio 1 water rein-
forcement schedule with a fixed 1-min time schedule for auto-
matic reinforcement. Thus, each response was reinforced, with
water also provided every minute in the absence of a response.
Rats that did not acquire lever-pressing behavior following three
daily 1-h sessions under this schedule were trained using the
method of successive approximation. Following acquisition of
lever-pressing behavior, rats were trained daily on DRL 18-s ses-
sions for ∼2 weeks, following which they were advanced to DRL
72-s sessions. Responding on these sessions became stable after
∼8 weeks. Experimental test sessions lasted for 1 h and were
conducted 5 days/week during light hours.
MOUSE APPARATUS AND TRAINING
Twelve operant-conditioning chambers (30.5 × 24.1 × 29.2 cm;
MED Associates, St. Albans, VT) were used for the DRL experi-
ments. The levers in these chambers were mounted on one wall
with an adjacent food magazine next to the lever in the middle
of the wall. A reinforced response caused a clicker apparatus to
activate and the pellet feeder to deposit one 45-mg sucrose pel-
let (BioServ, Frenchtown, NJ) into the food magazine. The house
light, which was mounted on the ceiling, was turned on when the
session began, remained on throughout the entire session, and
was turned off at the end of the session. Each experimental cham-
ber was enclosed in a melamine sound-attenuating cubicle and
equipped with a white noise generator to provide masking noise.
Each mouse was initially trained under a variable time 60-s
operant schedule for 5 days, followed by fixed ratio-1 ratio sched-
ule for 5 days. After the mice had acquired lever-pressing behav-
ior, they were trained during daily DRL 6-s sessions for ∼1 week,
then mice progressed through weekly ascending DRL require-
ments (12, 18, 24, 30 s) before moving to DRL 36-s sessions.
The responding on these sessions became stable after ∼6 weeks.
Experimental sessions lasted for 45min and were conducted 5
days/week during light hours.
DELAYED REINFORCEMENT OF LOW-RATE (DRL) DATA ANALYSES
Drugs were administered to the animals once or twice weekly with
at least 1 week between subsequent drugs to minimize possible
carryover effects. Drug treatments were administered on Tuesdays
and Fridays. No treatments were administered on other test days.
Wednesdays were control days. “Control” behavior was calculated
as the pooled mean lever presses or reinforcers received during
Wednesday sessions across all Wednesdays for the duration of
each study. Performance was normalized to percent of control by
dividing total responses (or reinforcers) for each drug or vehicle
treatment by the mean number of responses (reinforcers) in the
respective pooled control condition, multiplied by 100.
The data analyses were conducted on the raw response and
reinforcement data. All behavioral data are expressed as the
mean ± s.e.m. normalized to the control condition. The effects of
LSN2424100 (3–40mg/kg), SB334867 (3–40mg/kg), almorexant
(10–100mg/kg) along with its inactive enantiomer (100mg/kg),
and imipramine (1–15mg/kg) were analyzed using separate One-
Way repeated measures ANOVAs on responses and reinforce-
ments, followed by Dunnett’s post-hoc tests (alpha = 0.05).
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Table 1 | In vitro binding and functional activity at human recombinant OX1 and OX2 receptors.
Compound Receptor binding affinity, Ki(nM)a Functional antagonist activity, Kb (nM)b
OX1 OX2 hOX1 hOX2 rOX1 rOX2
LSN2424100 393 ± 47 (3) 4.49 ± 1.39 (3) 90.3 ± 17.7 (2) 0.44 ± 0.11 (3) 175 ± 41 (2) 0.83 ± 0.19 (2)
SB334867 173 ± 11 (3) >10,000 (3) 8.68 ± 1.76 (3) >10,000 (3) 7.1 ± 0.71 (3) >10,000 (3)
Almorexant (S) 21 ± 3.2 (2) 6.9 ± 0.18 (2) 2.32 ± 0.18 (3) 1.73 ± 0.35 (3) 3.2 ± 0.7 (4) 4.4 ± 1.6 (4)
Almorexant (R) >10,000 (2) >10,000 (2) >10,000 (2) >10,000 (2) NT NT
aRadioligand binding was performed using HEK293 membranes expressing either human OX1 or OX2 receptors in the presence of [125I]-orexin A with a 90min
incubation time. Data represent the mean ± s.e.m. performed on separate occasions with the number of independent experiments in parenthesis. (R) is the inactive
enantiomer of almorexant.
bInhibition of calcium mobilization from HEK293 cells stably expressing human or rat OX1 or OX2 receptors, respectively. Functional antagonist activity was
determined by measuring the effects of an EC70 concentration of orexin-A. Data represent the mean ± s.e.m. performed on separate occasions with the number
of independent experiments in parenthesis. NT = not tested.
RESULTS
RADIOLIGAND BINDING AND INTRACELLULAR CALCIUM
MOBILIZATION
Using both an orexin filtration binding assay and a functional
intracellular calcium mobilization assay performed in antago-
nist mode, LSN2424100 demonstrated selectivity for human OX2
receptors stably expressed in HEK293 cells over OX1 receptors
(Table 1). LSN2424100 was approximately 87-fold more potent
at OX2 with a Ki of 4.49 nM (OX1 Ki = 393 nM) in the recep-
tor binding assay. In the functional assay, LSN2424100 was over
200-fold more potent for human OX2 with a Kb = 0.44 nM
whereas the Kb for human OX1 was 90.3 nM. Similar results were
obtained in the rat OX receptor cell lines, with rat OX2 and OX1
Kb = 0.83 and 175 nM, respectively, indicating 210-fold selec-
tivity. Conversely, SB334867 was more selective for the human
OX1 receptor (Table 1). SB334867 was completely inactive at the
OX2 receptor in both the in vitro assays. The measured binding
affinity of SB334867 for the OX1 receptor was 173 nM. SB334867
showed potent inhibition of intracellular calcium mobilization,
with OX1 Kb in human and rat = 8.68 and 7.1 nM, respectively.
In addition to testing selective orexin agents, we also evaluated
the non-selective orexin antagonist, almorexant. The more active
S-enantiomer of almorexant demonstrated balanced activity for
both human OX1 and OX2 receptors (Table 1). The binding
affinities of (S)-almorexant for OX1 and OX2 receptors were
21 and 6.9 nM, respectively. Similarly, in the functional assay,
(S)-almorexant showed roughly equal potency at inhibiting intra-
cellular calcium mobilization in cells expressing hOX1 and hOX2
receptors, with Kb-values of 2.32 and 1.73 nM, respectively. The
(R)-enantiomer of almorexant was inactive in both assays.
RAT EXPOSURE AND UNBOUND FRACTION
Pharmacokinetic data for LSN2424100 in rats are summarized
in Table 2. LSN2424100 exhibits good exposure in Sprague–
Dawley rats after IP, but not PO, administration of a 30mg/kg
dose (AUC0−6 h = 1300 and 269 ng∗h/mL, respectively). Mean
maximum plasma concentrations observed following a single
30mg/kg IP and PO dose were 1170 and 196 ng/ml, respectively at
0.5 h post injection. Mean brain concentrations observed follow-
ing a single 30mg/kg IP and PO dose were 77.2 and 33.5 ng/g,
Table 2 | Pharmacokinetic datafor LY2424100a.
Parameterb 30mg/kg IP 30mg/kg PO
AUC0−6 h (ng*h/ml) 1300 269
Cmax (ng/ml) 1170 196
tmax (hr) 0.5 0.5
Brain concentrationc (ng/g) 77.2 33.5
Plasma concentrationc (ng/ml) 149 45.8
Brain:plasma ratioc 0.52 0.72
Fu (brain/plasma) 0.0089/0.0341
Ccu (brain/plasma, nM) 5.93/2.99 0.67/3.52
an = 2 cannulated rats/dose.
bAbbreviations: AUC0−6h, area under the concentration vs. time curve from time
0–6 h; Cmax , maximum observed drug concentration; tmax , time to maximum
observed drug concentration; Fu, fraction unbound in brain/plasma; Cu (unbound
or free concentration) = Ctotal × Fu.
cTwo hours post treatment.
respectively, at 2 h post injection. Unbound fraction in plasma
and brain were determined to be 0.0341 and 0.0089, respectively.
c-Fos EXPRESSION
Administration of LSN2424100 to subjects in home cages pro-
duced no effects on c-fos protein levels in the rat prefrontal
cortex, compared to vehicle treated subjects (p > 0.05; Figure 2).
However, restraint stress invoked a significant increase in c-fos
expression in vehicle treated rats [F(4, 28) = 23.19; p < 0.001],
and this effect was attenuated by pre-treatment with either
LSN2424100 or alprazolam (p < 0.05; Figure 2).
DRL
In rats, imipramine produced a significant antidepressant-like
response, characterized by a decrease in total lever presses emit-
ted (51% of control responding) at 10mg/kg [F(3, 68) = 10.16,
p < 0.0001] with a concomitant increase in reinforcers received
[210% of control responding; F(3, 68) = 14.47, p < 0.001;
Figure 3A]. Doses of 1 and 3mg/kg had no significant effect on
behavior. Raw (non-normalized) data for all DRL experiments
are provided in Supplementary Table S1. In mice, imipramine
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also produced an antidepressant-like signature, with an increase
in reinforcers received (330% of control, Figure 3B) at 15mg/kg
[F(4, 60) = 7.32, p < 0.001], and a concomitant decrease in lever
presses emitted [70% of control; F(4, 60) = 4.2, p < 0.005]. The
antidepressant-like effect of imipramine was maintained in mice
lacking OX1 receptors, as demonstrated by a dose-dependent
increase in reinforcers received up to 15mg/kg [206% of con-
trol; F(3, 44) = 3.33, p = 0.028; Figure 3C], and a decrease in
lever presses emitted (63% of control) but this difference did
not quite reach statistical significance [F(3, 44) = 2.64, p = 0.06;
Dunnett’s post-hoc test, p = 0.02; Figure 3C]. Lower doses of
imipramine did not affect lever pressing in mice lacking OX1
receptors. Similarly, imipramine produced antidepressant-like
effects in mice lacking OX2 receptors, with a significant effect
in both lever presses emitted [F(3, 44) = 6.63, p < 0.001] and
reinforcers received [F(3, 44) = 7.58, p < 0.001; 70 and 140% of
control, respectively, at 15mg/kg; Figure 3D].
In rats, SB334867 did not produce a significant change
in either reinforcers received or total lever presses made, at
doses up to 30mg/kg (Figure 4A). Importantly, the positive
control used in this test, imipramine, significantly increased rein-
forcers received [160% of control, F(4, 24) = 9.22, p < 0.001]
and decreased lever presses [64% of control, F(4, 24) = 16.21,
p < 0.001]. In mice, SB334867 did not significantly affect lever
presses emitted or reinforcers received up to 40mg/kg (p > 0.05;
Figure 4B). In mice lacking OX1 receptors, SB334867 pro-
duced a significant decrease in lever presses emitted at 20 and
40mg/kg (75 and 35% of control, respectively; F(5, 58) = 10.5,
p < 0.001), while only producing a significant increase in rein-
forcers received at 20mg/kg [166% of control; F(5, 58) = 3.95,
p < 0.005; Figure 4C]. Although an increase reinforcers received
was observed at 40mg/kg (123%), this was not significant. In
mice lacking OX2 receptors, SB334867 only produced a disrup-
tion of lever pressing at 40mg/kg [F(5, 58) = 17.79, p < 0.001;
Figure 4D]. At this dose, lever presses emitted were less than
20% of control, while reinforcers received were 75% of control,
indicative of the animals’ inability to behave within the scheduled
operant parameters.
(S)-Almorexant treatment in rats produced a significant
increase in reinforcers received [F(3, 30) = 4.09, p < 0.02;
Figure 5A], while the reduction in lever presses emitted did
not reach statistical significance (p > 0.05). The inactive enan-
tiomer (R)-almorexant produced no effect on behavior at
100mg/kg (ps> 0.05). In mice, (S)-almorexant produced a
significant increase in reinforcers received [>400% of control;
F(4, 28) = 5.95, p = 0.001], while also producing a significant
dose-related decrease in lever presses emitted [47% of control;
F(4, 28) = 6.46, p < 0.001; Figure 5B]. Again, (R)-almorexant
produced no significant effects on behavior at 100mg/kg. In mice
lacking OX1 receptors, all doses of (S)-almorexant reduced the
number of lever presses emitted [10–60mg/kg; F(4, 51) = 10.16,
p < 0.001] while a significant increase in reinforcers received
was observed at 10 and 40mg/kg [F(4, 51) = 4.39, p < 0.004;
Figure 5C], although these effects do not appear to be dose-
dependent. In these animals, (R)-almorexant also produced
effects similar to (S)-almorexant, with significant increases in
reinforcers received and a concomitant significant decrease in
FIGURE 2 | c-Fos protein expression in rat prefrontal cortex with and
without restraint stress. In the absence of stress, LSN2424100 (n = 7)
had no effect on c-fos levels compared to vehicle treated subjects
(p > 0.05; n = 7). Restraint stress significantly increased c-fos levels in
vehicle-treated rats (∗∗∗p < 0.001; n = 7), and this effect was blocked by
both LSN2424100 (†††p < 0.001; n = 6) and alprazolam (†p < 0.05; n = 6).
lever pressing [t(54) = 2.04, p < 0.05 and t(54) = 2.04, p < 0.05,
respectively]. In mice lacking OX2 receptors, the effect of (S)-
almorexant was completely abolished (ps > 0.05; Figure 5D). In
these mice, (R)-almorexant (100mg/kg) produced a significant
decrease in lever presses emitted [65% of control; t(54) = 2.04,
p < 0.05], but did not significantly affect the number of
reinforcers received.
When administered to rats, LSN2424100 produced a sig-
nificant increase in reinforcers received [Figure 6A; 170% of
control; F(4, 24) = 3.13, p = 0.033] at 30mg/kg, along with a sig-
nificant decrease in lever presses made [60 and 70 of control;
F(4, 24) = 4.64, p = 0.006] at 10 and 30mg/kg, respectively. In
mice, LSN2424100 produced an increase in reinforcers received
(up to 225% of control, Figure 6B), but this effect did not
reach statistical significance. LSN2424100 treatment did pro-
duce a significant decrease in lever presses emitted at 10mg/kg
[50% of control; F(3, 35) = 3.28, p = 0.032]. A higher dose of
20mg/kg produced a decrease in lever presses emitted, but
this result did not reach statistical significance (Figure 6B).
In mice lacking OX1 receptors, the antidepressant-like efficacy
of LSN2424100 was maintained, as demonstrated by a statis-
tically significant increase in reinforcers received at 20mg/kg
[200% of control; F(3, 36) = 2.98, p = 0.044], and a significant
decrease in lever presses emitted at this dose [50% of con-
trol; Figure 6C; F(3, 36) = 4.73, p = 0.007]. In mice lacking OX2
receptors, however, there was no significant change either in
reinforcers received or lever presses emitted with LSN2424100
doses administered up to 40mg/kg (Figure 6D), indicating
complete loss of antidepressant-like efficacy in OX2 knockout
mice.
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FIGURE 3 | Antidepressant-like effect of imipramine on DRL-72-s
responding in rats and DRL-36-s responding in mice. Consistent with
literature reports, imipramine produced a significant antidepressant-like
effect in both rat DRL-72-s (A; n = 12) and mouse DRL-36-s models (B;
n = 16), as demonstrated by a significant increase in reinforcers (p < 0.001
and p < 0.01, respectively) and significant decrease in total responses
emitted (p < 0.01 and p < 0.001, respectively). Importantly, the
antidepressant-like efficacy of imipramine was not altered in mice lacking
OX1 or OX2 receptors (C,D, respectively; n = 8). ∗p < 0.05 vs. respective
vehicle, Dunnett’s post-hoc analyses.
DISCUSSION
Herein, we describe the pharmacological characterization of a
structurally-novel OX2 receptor antagonist, LSN2424100, with
high affinity and selectivity for OX2 over OX1 receptors. In
vitro selectivity data for OX2 over OX1 receptors obtained
using radioligand binding and intracellular calcium mobi-
lization assays showed 87- and 205-fold selectivity, respec-
tively (210-fold selectivity in the rat functional assay). Results
showed that the two comparator compounds, SB334867 and
(S)-almorexant, possessed in vitro profiles in the expected
ranges, wherein SB334867 showed high affinity and selectivity
for OX1 receptors, while the dual orexin antagonist, almorex-
ant, showed roughly equal affinity for OX1 and OX2 recep-
tors. Pharmacokinetic data indicated that LSN2424100 exhibits
good exposure in male Sprague–Dawley rats after IP, but not
PO, administration of a 30mg/kg dose (AUC0−6 h = 1300 and
269 ng∗h/mL, respectively), suggesting its use as a tool compound
to evaluate the role of OX2 receptor signaling mechanisms in
preclinical models.
Here, we report that orexin-2 receptor antagonists, including
LSN2424100 and almorexant, exhibit antidepressant-like efficacy
in the rat DRL-72 sec model, at 20–30 and 100mg/kg, respec-
tively, as indicated by significant reductions in total lever presses
FIGURE 4 | SB334867 failed to produce antidepressant-like effects in
rat DRL-72-s or mouse DRL-36-s. (A) SB334867 did not affect total
responses or reinforcers received in male SD rats maintained on a DRL-72-s
schedule of responding within a dose range of 3–30mg/kg (n = 7).
Importantly, the positive control, imipramine, did produce an
antidepressant-like effect in this experiment at 10mg/kg; (B) no significant
effect of SB334867 was observed on total responses emitted or reinforcers
received in C57Bl/6 mice (n = 7); (C) significant decrease in total responses
emitted by mice lacking OX1 receptors at 20 and 40mg/kg (p < 0.01), with
a concomitant increase in reinforcers received at 20mg/kg (p < 0.01;
n = 8); (D) significant decrease in total responses emitted (p < 0.05)
without a concomitant increase in reinforcers received, by mice lacking
OX2 receptors, at 40mg/kg (n = 8). ∗p < 0.05 vs. respective vehicle,
Dunnett’s post-hoc analyses.
emitted along with concomitant increases in reinforcers received.
Our data are consistent with previous reports that increased
OX signaling produced anhedonia-like symptoms in rats (mea-
sured by intracranial self-stimulation) (Boutrel et al., 2005),
whereas almorexant produced antidepressant-like effects in a
model of chronic unpredictable mild stress (Nollet et al., 2012).
Interestingly, Nollet et al. (2011) demonstrated that chronic
unpredictable mild stress increased activation of dorsomedial
hypothalamus/perifornical area (DMH-PFA), where orexin cell
bodies are localized. Moreover, they reported that chronic
treatment with the SSRI, fluoxetine, reversed the DMH-PFA
activation, suggesting a role for orexin signaling in the patho-
physiology of depression and antidepressant treatment response
(Nollet et al., 2011). The OX1 antagonist SB334867 did not
produce antidepressant-like effects in the assays studied here.
Together, the pharmacological data suggest that OX2 receptor sig-
naling may be involved in modulating mood states. The results
presented here contradict other studies suggesting that increases
in orexin-dependent signaling may produce antidepressant-like
effects (Ito et al., 2008; Lutter et al., 2008; Scott et al., 2011). The
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FIGURE 5 | Antidepressant-like effect of almorexant on DRL-72-s
responding in rats and DRL-36-s responding in mice. (A)
dose-dependent increase in the number of reinforcers obtained by male SD
rats in DRL-72-s, with significant effects at 100mg/kg (p < 0.05), as well as
a lack of effect of the inactive enantiomer at 100mg/kg (n = 11); (B)
dose-dependent and significant increase in the number of reinforcers
obtained (p < 0.05) by C57Bl/6 mice in DRL-36-s at 100mg/kg and a
significant decrease (p < 0.05) in total responses emitted at 100mg/kg, as
well as lack of effect of the inactive enantiomer at 100mg/kg (n = 8); (C)
significant decrease in responses emitted at all doses tested (p < 0.05)
with a concomitant increase in reinforcers received at doses of 10 and
40mg/kg (p < 0.05) in mice lacking OX1 receptors (n = 8). However,
100mg/kg of the inactive enantiomer also produced significantly fewer
responses (p < 0.05) with a concomitant increase in reinforcers received
(p < 0.05) in mice lacking OX1 receptors; (D) almorexant failed to produce
antidepressant-like effects in mice lacking OX2 receptors, up to 100mg/kg
(n = 8). The inactive enantiomer (100mg/kg) significantly reduced total
responses emitted in mice lacking OX2 receptors (p < 0.05), without
significantly affecting reinforcers earned (n = 8). ∗p < 0.05 vs. respective
vehicle, Dunnett’s post-hoc analyses.
reason for this difference is unclear, butmay be related tomethod-
ological differences between labs. Efficacy in the forced swim test,
although useful in many respects, does not always translate to
clinical antidepressant efficacy (De Pablo et al., 1989). The DRL
model used here has strong construct and predictive validity, and
is less likely to produce false positive results (O’Donnell et al.,
2005; Zhang et al., 2009). Although less susceptible to false pos-
itive results due to motor effects, drugs that dramatically affect
food intake, as has been reported for orexin antagonists (Mieda
et al., 2006; Boutrel et al., 2010), can affect behavior in the DRL
model. However, LSN2424100 was found to have no direct effects
on food or water intake (Fitch et al., unpublished results; and see
Anderson et al., under review). Alternatively, differences between
our study and previous reports may be related to the use of mice
lacking the orexin peptide (Lutter et al., 2008) vs. mice lacking
individual OX1 or OX2 receptors (current study).
FIGURE 6 | Antidepressant-like effects of LSN2424100 on DRL-72-s
responding in rats and DRL-36-s responding in mice. (A)
dose-dependent increase in the number of reinforcers obtained by male SD
rats in DRL-72-s (n = 7), with a significant effect at 30mg/kg (p < 0.05) and
a significant decrease in total responses emitted at 10 and 30mg/kg
(p < 0.05); (B) a significant decrease in total responses emitted by C57Bl/6
mice in DRL-36-s at 10mg/kg (p < 0.05; n = 8); (C) antidepressant-like
efficacy of LSN2424100 is maintained in mice lacking OX1 receptors, with a
significant increase in reinforcers obtained and a significant decrease in
responses at 20mg/kg (p < 0.05; n = 8); (D) antidepressant-like effect of
LSN2424100 is lost in mice lacking OX2 receptors, as illustrated by lack of
significant effects in either responses emitted or reinforcers received at all
doses (n = 8). ∗p < 0.05 vs. respective vehicle, Dunnett’s post-hoc
analyses.
In addition to demonstrating antidepressant-like efficacy
of OX2 antagonists in the rat DRL-72 s model, we extend
the findings to demonstrate efficacy in a mouse DRL-36 s
schedule of reinforcement. Importantly, we demonstrate sim-
ilar antidepressant-like efficacy of imipramine in the mouse
that closely resembles effects observed in the rat DRL model.
In the mouse DRL model, LSN2424100 and almorexant pro-
duced antidepressant-like effects, similar to the effects observed
in rats (Figures 5, 6). Moreover, the antidepressant-like effects
of LSN2424100 and almorexant were completely abolished in
mice lacking OX2 receptors, confirming the critical role of OX2
receptor signaling in mediating mood and antidepressant-like
efficacy of the orexin antagonists tested here. Importantly, the
effects of imipramine were found to be similar in mice lacking
either OX1 or OX2 receptors, although efficacy appeared to be
blunted in mice lacking OX2 receptors (Figure 3D). It is possible
that the antidepressant-like phenotype observed in mice lack-
ing OX2 receptors (see non-normalized data in Supplementary
Table S1) may be responsible for the apparent blunted efficacy
in the normalized data. Nonetheless, the efficacy of imipramine
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was not lost in mice lacking OX2 receptors, indicating that
the antidepressant-like effects of imipramine are not mediated
through orexin signaling mechanisms. By extension, our data
further suggest that the antidepressant-like efficacy of OX2 and
dual orexin receptor antagonists are mechanistically distinct from
monoamine-based antidepressants. Considering the sleep distur-
bances often experienced by depressed individuals, the known
side effect of SSRIs to exacerbate or even produce sleep disruption
in depressed patients, and the robust sleep-enhancing properties
of orexin antagonists (Mayers and Baldwin, 2005; Riemann, 2007;
Thase et al., 2010), it seems plausible that selectively inhibiting
OX2 receptor signaling may provide additional clinical benefits
by simultaneously improving mood and sleep.
The OX1 antagonist, SB334867, appeared void of
antidepressant-like activity in rats and mice, although
antidepressant-like effects were observed in mice lacking
OX1 receptors. Our results differ from previous reports that
SB334867 produced antidepressant-like efficacy in the mouse
forced swim test and tail suspension test (Scott et al., 2011).
It has also been reported that mice lacking OX1 receptors had
an antidepressant-like phenotype, an effect which we failed to
replicate (Fitch et al., unpublished observations). The reason
for the apparent antidepressant-like efficacy of SB334867 in
mice lacking OX1 receptors is not known, but could involve
either compensatory upregulation of OX2 receptors in mice
with constitutive deletion of OX1 receptors, or perhaps some
off-target, non-orexin pharmacology of SB334867 that may be
either amplified or unmasked in the absence of OX1 receptors.
Indeed, off-target pharmacology of SB334867 has already been
reported by others, including activity at targets that may produce
antidepressant-like effects, such as monoamine transporters,
norepinephrine transporter, and 5-HT2C receptors (Gotter et al.,
2012). Thus, data from our lab supports previous suggestions that
SB334867 should not be considered OX1-selective. At the highest
dose of 40mg/kg, SB334867 produced behavioral disruption in
mice lacking OX2 receptors, as indicated by strong reductions
in total responding and concomitant reductions in reinforcers
received. The mechanism by which SB334867 disrupted behavior
in these mice is not known, but may be related to compensatory
upregulation of OX1 receptors in these mice, an increase in
functional sensitivity of OX1 receptors in the absence of OX2
receptors, or some unidentified off-target pharmacology of
SB334867. Further studies will be required to understand these
effects in the knockout mice.
Stress is a major trigger of depression and relapse to recur-
rent depressive episodes (Mazure, 1998). In rats, restraint stress
stimulates ventral tegmental area (VTA) dopamine cell activity
and c-fos expression in the mPFC, an area with dense recipro-
cal connections to the VTA that is known to be disrupted in
depression (Drevets et al., 2008; Valenti et al., 2011). We demon-
strate here that restraint stress-induced c-fos activation in the PFC
was significantly attenuated by pre-treatment with LSN2424100.
Our data are consistent with previous studies demonstrating that
restraint-stress induced mPFC activation, as measured by c-fos
expression in both rats and mice (Radley et al., 2006; O’Mahony
et al., 2010; Valenti et al., 2011), and extend those results to
demonstrate that orexin signaling may be involved in mediating
stress responses within corticolimbic circuits. Although we and
others have reported c-fos activation in the PFC in response
to restraint stress, others have reported that restraint stress did
not produce robust c-fos activation of hypothalamic orexin cells
(Furlong et al., 2009), suggesting that the orexin systemmaymod-
ulate stress responses in the PFC through indirect pathways rather
than by direct connections from hypothalamic cells where orexin
is synthesized. While the importance of the PFC in regulating
mood is well-established, the potential role of orexin in modu-
lating these circuits is unclear. Further studies will be required
to explore the exact mechanism by which orexin signaling may
modulate prefrontal cortical activation following restraint stress,
which may involve modulation of dopaminergic and noradren-
ergic neurotransmission (Borgland et al., 2008; Del Cid-Pellitero
and Garzon, 2011).
Elucidating the role of the orexin system in modulating the
complex physiological and behavioral traits associated with psy-
chiatric disorders, including depression, has been a complex
undertaking, confounded by a dearth of selective pharmacolog-
ical tools. With its suggested involvement in the regulation of
vigilance states, feeding and energy homeostasis, drug-seeking
behavior, and emotional processing (Mieda et al., 2006; Richards
et al., 2008; Aston-Jones et al., 2009; Boutrel et al., 2010; Sinton,
2011; Nollet and Leman, 2013), the orexin system appears to
play a critical role in maintaining equilibrium in the mam-
malian nervous system (Sinton, 2011). In pathological states
related to mood, arousal, or consummatory behaviors, the orexin
system may present opportunities for pharmacological interven-
tion with potentially beneficial outcomes. Recent research has
begun to shed light on the diverse signaling properties of orex-
ins. For example, it is known that OX1 and OX2 receptors can
couple, either directly or indirectly, to several G-protein effec-
tors, including Gq, Gi/o, and Gs, with the potential to confer
diverse signaling properties of either OXA or OXB through var-
ious intracellular pathways including phospholipase C, adeny-
lyl cyclase, phospholipase A2, and phospholipase D (reviewed
recently by Leonard and Kukkonen, 2014). However, little is
known about which molecular pathways mediate the diverse
physiological effects of orexins reported in the literature. Research
focused on elucidating these mechanisms will benefit from an
array of tools providing precise control of component function,
including OX2-selective antagonists, which have not been widely
tested to date with regard to potential antidepressant-like effi-
cacy. Pharmacological tools, in particular, afford the investigator
with an accessible, fast-acting and straightforward methodology
for manipulation of receptor functioning to gain insight into the
dynamics of receptor-ligand interactions, downstream physiolog-
ical processes, signaling mechanisms, and behavioral output in
preclinical models.
We demonstrate here that LSN2424100 is a novel orexin
receptor antagonist with high affinity and selectivity for OX2
receptors and favorable pharmacokinetics following IP doses
up to 30mg/kg, and propose its use as a structurally-unique,
synthetically-accessible tool for probing the role of OX2-
dependent signaling in rodent models. Moreover, we demonstrate
that LSN2424100 blocks stress-induced c-fos activation in the
mPFC and produces antidepressant-like efficacy in an established
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animal model of depression in both rats and mice. Moreover, the
antidepressant-like efficacy of LSN2424100 was completely abol-
ished in mice lacking OX2, but not OX1, receptors, indicating
a critical role of OX2-receptor-mediated signaling. In conclu-
sion, LSN2424100 represents a functional tool compound for the
investigation of OX2-receptor-mediated function, particularly in
mood disorders.
SUPPLEMENTARY MATERIAL
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